Invokana Heart Attack

Invokana Heart Attack
Invokana may be associated with a number of serious complications, including an increased risk of heart attack. In fact, clinical trials for the Type 2 diabetes medication suggested that the chance of heart attack rises among Invokana patients during early days of treatment.

Invokana Lawsuit Reviews

The nationwide law firm of Bernstein Liebhard LLP is investigating legal claims on behalf of individuals who may have been harmed by Invokana. If you or some one you love took Invokana and suffered a heart attack, please call (888) 994-5118 to discuss your case with one of our attorneys.

BREAKING NEWS: Invokana Heart Attack Lawsuit Filed in Kentucky Federal Court

August 2016: What may be the first Invokana heart attack lawsuit has been filed in the U.S. District Court, Western District of Kentucky. According to the complaint, the plaintiff suffered a myocardial infarction in July 2015, after he had been taking Invokana to treat Type 2 diabetes. He claim that the drug’s manufacturers misrepresented Invokana as a safe and effective diabetes treatment, and asserts that he would not have used the medication, or would have been adequately monitored for side effects, had he and his physician had been made aware of the serious risks potentially associated with its use. Read More

FDA’s Approval of Invokana Raises Questions

Invokana was the first SGLT2 inhibitor approved in the U.S. to treat Type 2 diabetes. However, its 2013 approval by the U.S. Food & Drug Administration (FDA) was not without controversy. While the agency’s Endocrinologic and Metabolic Drugs Advisory Committee had recommended approval of the drug by a margin of 10-to-5, many panel members also voiced concerns about its cardiovascular safety. A Briefing Document prepared in advance of the Committee’s January 2013 meeting raised a number of questions about Invokana’s possible heart side effects, noting that:

  • Clinical trials for Invokana indicated an elevated stroke risk, as well as a small increase in the risk of heart attacks within the first 30 days treatment.
  • Invokana was shown to raise LDL (bad) cholesterol and good (HDL) cholesterol. Elevated cholesterol levels are a major risk-factor for heart attack and stroke, especially in people with Type 2 diabetes.

Once the drug was approved for sale, the Invokana labeling did not include any warning about heart attacks or strokes. However, according to The New York Times, the FDA did order Johnson & Johnson to conduct five post-marketing studies, including a clinical trial to determine more definitively if the drug increases cardiovascular risks.

What is a Heart Attack?

A heart attack or myocardial infarction occurs when the flow of blood to the heart muscle becomes blocked. This results in damage to or death of part of the heart muscle.

Symptoms of a heart attack may include:

  • Chest pain or discomfort
  • Upper body discomfort
  • Shortness of breath
  • Cold sweat
  • Unusual fatigue (especially women)
  • Nausea and vomiting
  • Light-headedness or sudden dizziness

The symptoms of a heart attack can vary from person to person, and do not always begin with sudden, crushing chest pain. If you suspect that you or someone else is experiencing a heart attack, call 911 immediately. Don’t drive to the hospital. Instead, wait for an ambulance so that emergency medical personnel can begin life-saving treatment a soon as they arrive.

Am I Eligible to File an Invokana Lawsuit

If you suffered a heart attack while taking Invokana, the attorneys at Bernstein Liebhard LLP can help you determine if you have a valid claim for compensation. To learn more about filing an Invokana lawsuit, please call (888) 994-5118.

  1. MedScape (2013) “Most FDA advisors support diabetes drug canagliflozin, despite CV concerns” http://www.medscape.com/viewarticle/791413
  2. FDA (2013) “FDA Briefing Document – Invokana (canagliflozin) Tablets” http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf
  3. New York Times (2013) “F.D.A. Approves a New Diabetes Drug From J.&J.” http://www.nytimes.com/2013/03/30/business/invokana-wins-fda-approval-for-diabetes-treatment.html?_r=2

Save

Last Modified: September 8, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.

 
 
 

Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest

Skip to content